CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows:
TD Cowen 45th Annual Health Care Conference | ||
Company presentation: | Wednesday March 5, 2025 | |
Time: | 3:10 PM ET |
To request a meeting or for more details about the conferences please reach out to your institutional contact or email.
The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.18 |
Daily Change: | -0.03 -1.14 |
Daily Volume: | 488,256 |
Market Cap: | US$121.600M |
May 13, 2025 March 27, 2025 January 10, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load